The Dow posted a modest loss on Friday.

While they were minor gains for the S and P 500 the NASDAQ longer term, Wall Street snapped a three week winning streak.

Greg Hahn, chief investment officer at With Capital Management.

We think we're in a holding pattern.

We think we have to see what happens with Stimulus Right now.

I think portfolio managers air looking at getting portfolios in shape heading into the end of the year.

So we're gonna start to see tax loss, harvesting some positional trading.

But in terms of of altering the portfolio with respect to stock selection right now, I think we just have to wait and see what stimulus looks like.

It's been a good it's been a good three weeks.

Though there were a number of earnings duds, American Express missed third quarter profit estimates.

Its cardholders, who tend to skew more affluent, spent roughly 20% less over the past three months.

Profits also took a hit from the $665 million Amex set aside to cover card spending than might go unpaid.

Shares of chipmaker Intel tumbled 10.5%.

Wall Street frowned upon a quarterly sales mix that bent MAWR towards less profitable chips for cheaper laptops and slower government data center spending.

But in three bright spots, Gilead Sciences rose after its anti viral drug Rendez Affair became the first and Onley drug to get US approval for treating patients hospitalized with Cove.

In 1930 FDA gave AstraZeneca the green light to restart late stage clinical trials for experimental covert 19 vaccine.

U.

S trials were halted for more than a month after a report of a serious neurological illness in a British participant.

And Johnson and Johnson says it has been cleared to resume its covert 19 vaccine trials after it was briefly halted due to what it called a serious medical event.